Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 2
Submit an article Journal homepage
2,531
Views
15
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML

Erik Delsing Malmberga Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden;
,
Sofie Johansson Alma Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden;
,
Malin Nicklassonb Department of Medicine, Section of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden;
,
Vladimir Lazarevicc Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden;
,
Sara Ståhlmand Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden;
,
Tore Samuelssone Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden;
,
Stig Lenhoffc Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden;
,
Julia Aspa Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; ;d Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden;
,
Mats Ehingerf Division of Oncology and Pathology, Lund University, Lund, Sweden
,
Lars Palmqvista Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; ;d Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden;
,
Mats Bruneb Department of Medicine, Section of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden;
&
Linda Fogelstranda Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; ;d Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden; Correspondence[email protected]
 show all
Pages 409-417 | Received 12 Feb 2018, Accepted 27 May 2018, Published online: 02 Aug 2018

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Yuye Shi, Yuhao Xue, Chunling Wang & Liang Yu. (2022) Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia. Hematology 27:1, pages 609-619.
Read now
Tingyu Yu, Jianxiang Chi & Li Wang. (2021) Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia. Hematology 26:1, pages 848-859.
Read now

Articles from other publishers (13)

Michael Krigstein, Harry J. Iland & Andrew H. Wei. (2023) Applying molecular measurable residual disease testing in acute myeloid leukaemia. Pathology 55:1, pages 1-7.
Crossref
Katalin Kelemen. (2022) The Role of Nucleophosmin 1 (NPM1) Mutation in the Diagnosis and Management of Myeloid Neoplasms. Life 12:1, pages 109.
Crossref
Anne E. Austin & Michael Byrne. (2021) Detecting and preventing post-hematopoietic cell transplant relapse in AML. Current Opinion in Hematology 28:6, pages 380-388.
Crossref
Amanda Lopez, Sanjay Patel, Julia T. Geyer, Joelle Racchumi, Amy Chadburn, Paul Simonson, Madhu M. Ouseph, Giorgio Inghirami, Nuria Mencia-Trinchant, Monica L. Guzman, Alexandra Gomez-Arteaga, Sangmin Lee, Pinkal Desai, Ellen K. Ritchie, Gail J. Roboz, Wayne Tam & Michael J. Kluk. (2021) Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. Frontiers in Oncology 11.
Crossref
Louise Pettersson, Sofie Johansson Alm, Alvar Almstedt, Yilun Chen, Gustav Orrsjö, Giti Shah‐Barkhordar, Li Zhou, Heike Kotarsky, Karina Vidovic, Julia Asp, Vladimir Lazarevic, Lao H. Saal, Linda Fogelstrand & Mats Ehinger. (2021) Comparison of RNA‐ and DNA‐based methods for measurable residual disease analysis in NPM1 ‐mutated acute myeloid leukemia . International Journal of Laboratory Hematology 43:4, pages 664-674.
Crossref
Selina M. Luger. (2021) Consolidation Therapy for Acute Myeloid Leukemia: Defining a Benchmark. Journal of Clinical Oncology 39:8, pages 870-875.
Crossref
Sanam Loghavi, Courtney D. DiNardo, Ken Furudate, Koichi Takahashi, Tomoyuki Tanaka, Nicholas J. Short, Tapan Kadia, Marina Konopleva, Rashmi Kanagal‐Shamanna, Noushin R. Farnoud, Sherry Pierce, Joseph D. Khoury, Jeffrey L. Jorgensen, Keyur P. Patel, Naval Daver, Musa Yilmaz, L. Jeffrey Medeiros, Hagop Kantarjian, Farhad Ravandi & Sa A. Wang. (2021) Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1 ‐mutated acute myeloid leukaemia . British Journal of Haematology 192:6, pages 1054-1063.
Crossref
Ying Wang & Richard Press. 2021. Blood and Marrow Transplant Handbook. Blood and Marrow Transplant Handbook 929 941 .
Alexandros Spyridonidis. (2020) How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation. Blood 135:19, pages 1639-1649.
Crossref
Edward AbadirPablo A. Silveira, Robin E. Gasiorowski, Murari RameshAdelina RomanoAhmed H. Mekkawy, Tsun-Ho Lo, Karieshma KabaniSarah Sutherland, Geoffrey A. Pietersz, P. Joy HoChristian E. BryantStephen R. LarsenGeorgina J. Clark. (2020) Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia. Blood Advances 4:7, pages 1206-1216.
Crossref
Edward Abadir, Robin E. Gasiorowski, Pablo A. Silveira, Stephen Larsen & Georgina J. Clark. (2020) Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia?. Journal of Clinical Medicine 9:2, pages 554.
Crossref
Nikhil Patkar, Rohan Kodgule, Chinmayee Kakirde, Goutham Raval, Prasanna Bhanshe, Swapnali Joshi, Shruti Chaudhary, Y. Badrinath, Sitaram Ghoghale, Shraddha Kadechkar, Syed Hasan Khizer, Sadhana Kannan, Dhanalaxmi Shetty, Anant Gokarn, Sachin Punatkar, Hasmukh Jain, Bhausaheb Bagal, Hari Menon, Manju Sengar, Navin Khattry, Prashant Tembhare, Papagudi Subramanian & Sumeet Gujral. (2018) Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia . Oncotarget 9:93, pages 36613-36624.
Crossref
Fabio Forghieri, Patrizia Comoli, Roberto Marasca, Leonardo Potenza & Mario Luppi. (2018) Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives. International Journal of Molecular Sciences 19:11, pages 3492.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.